 I. To determine the maximally tolerated dose MTD and recommended dosing for the combination of CCI-779 and Bevacizumab in patients with metastatic renal cell cancer. Phase I II. To determine the proportion of patients with metastatic renal cell cancer who are progression free at 6 months. Phase II 